
Loading, please wait...

Loading, please wait...
"Wherever the art of Medicine is loved, there is also a love of Humanity."
Hippocrates

The new preparation technique offers several distinct advantages over traditional methods. Furthermore, the use of aza-Michael addition allows for the fabrication of these particles under mild conditions. Consequently, this preserves the integrity of the polypeptide chains while ensuring high structural stability. Additionally, researchers can precisely control the size and compactness of the particles. This flexibility allows for the creation of a diverse library of nanoparticles tailored for specific biomedical studies. Moreover, these nanoparticles exhibit excellent stimuli-responsiveness, which is crucial for controlled drug release within the body.
Specifically, the team demonstrated the practical utility of these SCNPs through surface modification. By creating anionic surfaces, they successfully developed nanoparticles with a high affinity for bone tissue. Thus, these **bone-targeting polypeptide nanoparticles** can effectively carry therapeutic agents directly to the skeletal system. This targeted approach minimizes systemic side effects and enhances the efficacy of treatments for bone-related disorders. In addition, the use of naturally inspired polypeptides ensures better biocompatibility and degradability. We believe this work provides a robust framework for future applications in regenerative medicine and targeted oncology.
These nanoparticles use specific surface modifications to create an anionic charge. This charge allows them to target bone tissue more effectively than non-modified polymers. Furthermore, the mild synthesis conditions keep the targeting ligands functional.
Yes, because they are made from biodegradable polypeptide precursors. Unlike earlier synthetic versions, these particles break down safely in biological environments, which reduces long-term toxicity concerns.
Aza-Michael addition works in an aqueous environment and does not require harsh chemicals. Therefore, the process is more environmentally friendly and safer for incorporating sensitive biological molecules.
Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Refer to the latest local and national guidelines for clinical practice.
References
Xu H et al. Facile preparation, structural modulation, and bone-targeting of single-chain polypeptide nanoparticles. J Mater Chem B. 2026 Jun 19. doi: 10.1039/d6tb00846a. PMID: 42318760.
Hamelmann NM. Single-Chain Polymer Nanoparticles in Controlled Drug Delivery. Thesis, University of Twente. 2022. doi: 10.3990/1.9789036554398.
Wang B et al. Selection of Bone-Targeting Peptides for Therapeutic Intervention: An In Vivo Evaluation and Comparison Study. bioRxiv. 2024. doi: 10.1101/2024.12.10.627772.

Researchers have developed a facile method to prepare bone-targeting polypeptide nanoparticles using aza-Michael addition in aqueous environments. These biodegradable SCNPs offer adjustable size and stimuli-responsiveness, making them a promising platform for targeted orthopedic drug delivery.
Today

Recent studies reveal that Erdheim-Chester disease can manifest as glomeruloid haemangiomas driven by elevated VEGF-A levels. This discovery highlights a paracrine mechanism involving MAPK-activated histiocytes, providing new insights into the atypical cutaneous manifestations of this rare histiocytic neoplasm.
Today

A study confirms that short-course preoperative endocrine therapy significantly reduces Ki67 levels in ER-positive breast cancer, with the MammaPrint assay acting as a key predictor of this functional response.
Today

Researchers from IIT Bombay, IISER Pune, and IISER Kolkata have discovered a novel peptide, KTDP, that blocks the motor protein kinesin-1 to lower blood lipids by 50%. Crucially, this mechanism does not cause fat buildup in the liver, offering a safer preclinical pathway for metabolic and cardiovascular therapy.
Today

Researchers have developed a modular PEG-based scaffold that simplifies the creation of multi-agonist peptide therapeutics. Using GLP-1 and amylin agonists as a model, this platform enables rapid, modular assembly of potent multi-receptor drugs, offering a new route for treating obesity and metabolic diseases.
Today